ArticleCancer science2008
Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinomas.
Article in Cancer science, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 48 citations in OpenAlex.
- MMP-7 is upregulated by COX-2 and promotes proliferation and invasion of lung adenocarcinoma cells.European journal of histochemistry : EJH · 2014Trial
- MMP7, Regulated by c-Jun, is Involved in Oral Squamous Cell Carcinoma and Associated with Cancer-Related Fibroblasts Infiltration.Current cancer drug targets · 2025Article
- Selected Cytokines and Metalloproteinases in Inflammatory Bowel Disease.International journal of molecular sciences · 2023Review
- FKBP51 promotes invasion and migration by increasing the autophagic degradation of TIMP3 in clear cell renal cell carcinoma.Cell death & disease · 2021Article
- Elevated matrix metalloproteinase 7 expression promotes the proliferation, motility and metastasis of tongue squamous cell carcinoma.BMC cancer · 2020Article
- LINK-A lncRNA is upregulated in metastatic non-small cell lung cancer and is associated with poor prognosis.Oncology letters · 2019Article
- MMP-7 expression may influence the rate of distant recurrences and disease-specific survival in HPV-positive oropharyngeal squamous cell carcinoma.Virchows Archiv : an international journal of pathology · 2018Article
- Antcin-H Isolated fromEvidence-based complementary and alternative medicine : eCAM · 2017Article
- Matrix Metalloproteinases-7 and Kidney Fibrosis.Frontiers in physiology · 2017Review
- A Pilot Study Evaluating Serum MMP7 as a Preoperative Prognostic Marker for Pancreatic Ductal Adenocarcinoma Patients.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2016Article
- Validation of the diagnostic and prognostic relevance of serum MMP-7 levels in renal cell cancer by using a novel automated fluorescent immunoassay method.International urology and nephrology · 2016Article
- Imbalance between MMP-2, 9 and TIMP-1 promote the invasion and metastasis of renal cell carcinoma via SKP2 signaling pathways.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Serum Matrix Metalloproteinase-7 is an independent prognostic biomarker in advanced bladder cancer.Clinical and translational medicine · 2014Article
- Overexpression of MMP-7 Increases Collagen 1A2 in the Aging Kidney.Physiological reports · 2013Article
- Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Review
- The plasma membrane sialidase NEU3 regulates the malignancy of renal carcinoma cells by controlling β1 integrin internalization and recycling.The Journal of biological chemistry · 2012Article
- Matrix metalloproteinase-7 as a surrogate marker predicts renal Wnt/β-catenin activity in CKD.Journal of the American Society of Nephrology : JASN · 2012Article
- Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer.Pathology oncology research : POR · 2011Article
- Matrix metalloproteinases and their clinical relevance in urinary bladder cancer.Nature reviews. Urology · 2011Review
- Autoantibodies against MMP-7 as a novel diagnostic biomarker in esophageal squamous cell carcinoma.World journal of gastroenterology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated the clinical usefulness of plasma matrix metalloproteinase-7 (MMP-7) as a diagnostic and prognostic biomarker in patients with renal cell carcinoma (RCC). MMP-7 was quantified in plasma of 50 healthy subjects and 97 RCC patients using a Fluorokine MultiAnalyte Profiling assay. RCC patients were stratified into the following groups: without metastases (N0M0; n = 39), with lymph nodes (N1M0; n = 13), and with distant metastases (M1; n = 45). Diagnostic performance of MMP-7 was analyzed by the receiver operating characteristics (ROC) curve. Kaplan-Meier analysis and the Cox regression model were used to estimate the impact of MMP-7 on the cancer-specific survival outcome of RCC patients. MMP-7 was significantly higher in both metastatic groups N1M0 and M1 (medians, 3.82 and 3.34 microg/L) compared to N0M0 group or controls (medians, 1.85 and 1.64 microg/L; all P < 0.001). In ROC analysis, the area under the ROC curve of MMP-7 was 0.80 in the detection of metastases in RCC (P < 0.0001). In the Kaplan-Meier analysis, patients with MMP-7 above the 95th percentile of controls showed less favorable survival rates compared to those with normal MMP-7 (log-rank test, 15.7; P < 0.0001). High MMP-7 was associated with cancer-related mortality estimated by univariate Cox regression (risk ratio, 4.34, 95% CI, 1.12-10.6; P = 0.032). The multivariate Cox regression model determined MMP-7 (risk ratio, 2.70, 95% CI, 1.39-5.24; P = 0.003) and metastases (risk ratio, 5.81, 95% CI, 2.77-12.2; P < 0.0001) as independent determinants of cancer-related survival outcomes. In conclusion, increased plasma MMP-7 could be related to metastatic disease and poor prognosis in patients with RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.